115016-99-4 Usage
Description
(+)-Profenamine, also known as profenamine or N-ethyldiethanolamine, is a chemical compound that belongs to the class of tertiary amines. It is primarily recognized for its antiarrhythmic properties, making it a valuable asset in the treatment of various cardiac arrhythmias.
Used in Pharmaceutical Industry:
(+)-Profenamine is used as an antiarrhythmic agent for its ability to treat various cardiac arrhythmias. It functions by blocking the fast inward sodium current in cardiac cells, which aids in stabilizing the electrical activity of the heart and preventing abnormal heart rhythms.
Additionally, (+)-Profenamine is being explored for its potential anti-inflammatory and analgesic properties, indicating that it may have broader applications in the medical field beyond its current use as an antiarrhythmic agent. Further research is necessary to fully understand and harness these potential benefits.
Check Digit Verification of cas no
The CAS Registry Mumber 115016-99-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,5,0,1 and 6 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 115016-99:
(8*1)+(7*1)+(6*5)+(5*0)+(4*1)+(3*6)+(2*9)+(1*9)=94
94 % 10 = 4
So 115016-99-4 is a valid CAS Registry Number.
115016-99-4Relevant articles and documents
CONTROLLED RELEASE COMPOSITIONS AND METHODS FOR USING SAME
-
Page 30, (2010/02/06)
Pharmaceutical preparations adapted for mucosal delivery, preferably for nasal delivery, which can be easily and safely used over days to weeks with minimal side effects. The pharmaceutical preparations comprise microcapsules comprising at least one pharmaceutically active agent. The microcapsules provide controlled release of the pharmaceutically active agent. Cytotoxicity is avoided for cytotoxic pharmaceutically active agents and/or for cytotoxic dosages by one or more of the following: (a) manipulating the mucosal transport rate of the pharmaceutically active agent through the mucosal bodies to achieve a transport rate which is substantially the same as the controlled release rate, and/or (b) selecting only a most active and/or less cytotoxic enantiomer of the pharmaceutically active agent for use in the pharmaceutical preparation.
Stability of some phenothiazine free radicals.
Levy,Tozer,Tuck,Loveland
, p. 898 - 905 (2007/10/10)
-
